TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30479999

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered by respiratory nurses
Number of subjects: 279

Group type: COMPARATOR
Intervention: Self-help leaflets
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 279
Study: 26965712

Group type: EXPERIMENTAL
Intervention: Oral supplementation enriched with EPA, arginine, and nucleotides before the operation (group IN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No artificial nutrition before the operation (group C)
Number of subjects: 40
Study: 22648463

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MICT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-training control group
Number of subjects: 60
Study: 20525985

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 2039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2039
Study: 17654236

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (simulated altitude from 4000 to 5500 m) for 3 h per day, 5 days a week, for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control normoxic group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure
Number of subjects: 16
Study: 16147771

Group type: EXPERIMENTAL
Intervention: Experimental model of teaching/learning based on a research project
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (traditional model of practical activity)
Number of subjects: 173
Study: 11792923

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg twice daily for 3 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nimodipine and Placebo (regardless of initial treatment)
Number of subjects: 86
Study: 10418208

Group type: EXPERIMENTAL
Intervention: Early group (116 patients) - upper arm exercises starting on the third post-operative day
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Later group (115 patients) - upper arm exercises starting on the sixth post-operative day
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Delayed group (113 patients) - upper arm exercises after all drains were removed
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Delayed group (113 patients)
Number of subjects: 344
Study: 7554973

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and gestodene (EE/GSD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Monophasic formulation containing 35 micrograms ethinylestradiol and 250 micrograms norgestimate (EE/NGM)
Number of subjects: 46
Study: 2345268

Group type: EXPERIMENTAL
Intervention: Progesterone gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol gel
Number of subjects: 0
Study: 7212503

Group type: EXPERIMENTAL
Intervention: Semiquantitative glucose measurements of spot urine specimens
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Number of subjects: 246
Study: 30703780

Group type: EXPERIMENTAL
Intervention: Video-assisted consent
Number of subjects: 200

Group type: COMPARATOR
Intervention: Verbal consent
Number of subjects: 200
Study: 27717999

Group type: EXPERIMENTAL
Intervention: Dabigatran EM with bosutinib (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran EM alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran EM with bosutinib
Number of subjects: 0
Study: 26123638

Group type: EXPERIMENTAL
Intervention: ECMO with roller pump
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matched control
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ECMO with centrifugal pump
Number of subjects: 22
Study: 25073669

Group type: EXPERIMENTAL
Intervention: 750 mg/day of biphenyl dimethyl dicarboxylate (DDB)
Number of subjects: 135

Group type: COMPARATOR
Intervention: 300 mg/day of ursodeoxycholic acid (UDCA)
Number of subjects: 135
Study: 22186979

Group type: EXPERIMENTAL
Intervention: HZT-501 (ibuprofen 800 mg + double-dose famotidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen alone (800 mg)
Number of subjects: 0
Study: 19237607

Group type: EXPERIMENTAL
Intervention: NDRG2-expressing plasmid transfection in SW620 colon cancer cell line
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mutant NDRG2 (deletion or site-directed mutagenesis)
Number of subjects: 99
Study: 16860964

Group type: EXPERIMENTAL
Intervention: Detailed numerical information (absolute/relative risk, numbers-needed-to-treat)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: 'Anchoring' to familiar risks or descriptions
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Graphical (bar charts, thermometer scales, crowd figure formats)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Combination of 1-3
Number of subjects: 710

Group type: COMPARATOR
Intervention: Control group information based on British Medical Journal 'Best Treatments'
Number of subjects: 710
Study: 12534408

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole (n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 40 mg pantoprazole (n = 24)
Number of subjects: 50
Study: 10650302

Group type: EXPERIMENTAL
Intervention: Estrogen/progestin replacement therapy
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: High HDL-C (defined by NCEP)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Independent correlates of high HDL-C
Number of subjects: 2763
Study: 9023640

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg and amoxycillin 1000 mg twice daily for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Omeprazole 20 mg and placebo twice daily for 14 days
Number of subjects: 28
Study: 1641608

Group type: EXPERIMENTAL
Intervention: Negative-thought-reduction
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Placebo procedure (imagine high anger‐arousing situations)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 29
Study: 6423896

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 2
Study: 30020252

Group type: EXPERIMENTAL
Intervention: Web-based physical activity promotion program (WPAPP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 28069480

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 μg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 μg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 μg)
Number of subjects: 120
Study: 25566817

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 or 50 mg for 6 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24059992

Group type: EXPERIMENTAL
Intervention: TwHF (1‐2 mg·kg⁻¹·d⁻¹)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Irbesartan (150‐300 mg/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TwHF combined with irbesartan (TwHF 1‐2 mg·kg⁻¹·d⁻¹ + irbesartan 150‐300 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study: 21716965

Group type: EXPERIMENTAL
Intervention: Immediate loading of implants following the Columbus Bridge Protocol (4 to 6 implants loaded within 24 hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Delayed loading of implants following the ad modum Branemark protocol (6 to 9 implants loaded a mean 8.75 months after surgery)
Number of subjects: 49
Study: 19220905

Group type: EXPERIMENTAL
Intervention: Traditional media (journals, colleagues, quality circles)
Number of subjects: 449

Group type: COMPARATOR
Intervention: New media (internet)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Requirements for media in medical education
Number of subjects: 449
Study: 16446006

Group type: EXPERIMENTAL
Intervention: Prototype formulation of metoprolol succinate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation Beloc-zok
Number of subjects: 12
Study: 15285544

Group type: EXPERIMENTAL
Intervention: Radiofrequency excision of sentinel pile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional excision of sentinel pile
Number of subjects: 0
Study: 11447769

Group type: COMPARATOR
Intervention: Intravenous 2 mg tropisetron (single injection)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intravenous 2 mg tropisetron (daily for 5 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Peroral daily treatment with 5 mg tropisetron
Number of subjects: 42
Study: 9625105

Group type: EXPERIMENTAL
Intervention: 8.7 mg every 2 weeks (group A)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 29.7 mg every month (group B)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 148.2 mg every 3 months (group C)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 382 mg every 6 months (group D)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 993 mg once (group E)
Number of subjects: 304
Study: 7871323

Group type: EXPERIMENTAL
Intervention: Technique applied by operators with previous experience (Group 1)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Technique applied by operators with no previous experience under supervision (Group 2)
Number of subjects: 98
Study: 3045295

Group type: EXPERIMENTAL
Intervention: Captopril (6 mg orally)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Saralasin acetate (50 ng kg‐1 min‐1 intravenous infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carrier alone
Number of subjects: 30
Study: 29236228

Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 25 mg
Number of subjects: 60
Study: 27762642

Group type: EXPERIMENTAL
Intervention: Black eyelash mascara + Nd:YAG laser (Group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Black eyelash mascara + Alexandrite laser (Group II)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (Nd:YAG laser only for Group I)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (Alexandrite laser only for Group II)
Number of subjects: 36
Study: 25654520

Group type: EXPERIMENTAL
Intervention: Weight Management (WM) program
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: WM+ program (behavior modification)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 550
Study: 23719546

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 20 mg · kg(‐1) · d(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19481738

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic myomectomy using Laparotenser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional laparoscopic myomectomy (control group)
Number of subjects: 30
Study: 18258715

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with paclitaxel plus carboplatin followed by interval debulking surgery and an additional four cycles of postsurgical chemotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS) followed by eight cycles of postsurgical chemotherapy with or without interval debulking surgery
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 300
Study: 16466688

Group type: EXPERIMENTAL
Intervention: Videoconferencing-based cognitive-behavioral therapy (CBT)
Number of subjects: 3
Study: 14587411

Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (Iomeprol 300 mgI/ml or 350 mgI/ml) only
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (300 mgI/ml or 350 mgI/ml) flushed with 50 ml of saline solution at a rate of 5 ml/sec
Number of subjects: 108
Study: 12141525

Group type: EXPERIMENTAL
Intervention: Surfactant treatment in infants with RDS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (preterm infants without RDS)
Number of subjects: 21
Study: 9562652

Group type: EXPERIMENTAL
Intervention: Accelerated protocol: 1.5 M.U. streptokinase infused in 20 min (subgroup A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard protocol: 1.5 M.U. streptokinase infused in 60 min (subgroup B)
Number of subjects: 100
Study: 8461077

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 118

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 118
Study: 3324526

Group type: EXPERIMENTAL
Intervention: Verapamil (mean, 493 +/- 136 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Propranolol (mean, 340 +/- 135 mg/day)
Number of subjects: 74
Study: 31726490

Group type: EXPERIMENTAL
Intervention: Intrapleural infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Number of subjects: 43
Study: 29273441

Group type: EXPERIMENTAL
Intervention: Non-contrast high-resolution T2WI
Number of subjects: 67
Study: 27860499

Group type: EXPERIMENTAL
Intervention: Insulin LM75/25
Number of subjects: 54

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 54
Study: 24438516

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis (60 minutes on a cycle ergometer)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (no aerobic exercise)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis
Number of subjects: 132
Study: 21742599

Group type: EXPERIMENTAL
Intervention: Hyperthyroid patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control participants (euthyroid healthy participants)
Number of subjects: 40
Study: 19443788

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Noncontingent Reinforcement (NR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Relaxation Control
Number of subjects: 110
Study: 17632765

Group type: EXPERIMENTAL
Intervention: Prior history of gallbladder disease
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: Gallbladder disease not caused by cholelithiasis
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: Cholelithiasis diagnosed within the year before pancreatic cancer
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: Cholelithiasis and cholecystectomy within the same time frame
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: Gastric and/or duodenal ulcers of ≤2 years duration
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: Hyperthyroidism
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: Other thyroid conditions
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: At least one first-degree relative with pancreatic cancer
Number of subjects: 2233
Study: 14724396

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 660

Group type: COMPARATOR
Intervention: Women
Number of subjects: 660
Study: 11818027

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) with a dose of 12-15 Gy (median 15 Gy) followed by postoperative external radiation therapy (EXRT) with a median total dose of 60 Gy.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group treated with postoperative external radiation therapy (EXRT) alone.
Number of subjects: 32
Study: 10723515

Group type: EXPERIMENTAL
Intervention: Didanosine plus stavudine plus hydroxyurea
Number of subjects: 144

Group type: COMPARATOR
Intervention: Didanosine plus stavudine
Number of subjects: 144
Study: 7864328

Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 micrograms.kg‐1 on induction of anaesthesia, followed by alfentanil 7.5 micrograms.kg‐1 90 s before surgical incision (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil 15 micrograms.kg‐1, 10 min after abdominal incision (group B)
Number of subjects: 60
Study: 2376428

Group type: EXPERIMENTAL
Intervention: Dextromethorphan-salbutamol combination tablet (Redol comp)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Plain dextromethorphan tablet (Extuson)
Number of subjects: 10
Study: 14503

Group type: EXPERIMENTAL
Intervention: Acebutolol (2.0 g total dosage over 48 hours)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 44
Study: 31997647

Group type: EXPERIMENTAL
Intervention: Adapted alternating treatments design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative methods (e.g., random assignment)
Number of subjects: 0
Study: 31301748

Group type: EXPERIMENTAL
Intervention: Standing frame programme plus usual care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 28454792

Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly (EQW)
Number of subjects: 14752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14752
Study: 26120790

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 47
Study: 23531167

Group type: EXPERIMENTAL
Intervention: AdWords campaign based on keywords related to 'Eastenders' and 'cervical cancer'
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ten practices not using the AdWords campaign)
Number of subjects: 10
Study: 21752951

Group type: EXPERIMENTAL
Intervention: Meningococcal group A conjugate (PsA‐TT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1/5 dose of Meningococcal ACWY polysaccharide (PsACWY)
Number of subjects: 0
Study: 19710585

Group type: EXPERIMENTAL
Intervention: School-based sore throat clinic program with free nurse-observed oral penicillin treatment of group A streptococcal pharyngitis
Number of subjects: 22000

Group type: COMPARATOR
Intervention: Routine general practice care (Control)
Number of subjects: 22000
Study: 22852485

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 2 hours with intermittent exercise at a DEP mass concentration near 100 microg/m3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2) exposure near 0.35 ppm
Number of subjects: 30
Study: 16433278

Group type: EXPERIMENTAL
Intervention: Genetic attribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no genetic attribution)
Number of subjects: 0
Study: 12890841

Group type: EXPERIMENTAL
Intervention: High-dose bevacizumab (10 mg/kg every two weeks)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Low-dose bevacizumab (3 mg/kg every two weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 116
Study: 10199350

Group type: EXPERIMENTAL
Intervention: Spinal-cord stimulation in addition to best medical treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 120
Study: 7766296

Group type: EXPERIMENTAL
Intervention: Low-dose OKT3 (0.5 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional dose OKT3 (5 mg daily)
Number of subjects: 22
Study: 2279744

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide using medicated plastic porous tape (8 micrograms/cm2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fluocinolone acetonide using 0.025% cream
Number of subjects: 18
Study: 7437907

Group type: EXPERIMENTAL
Intervention: Pizotifen 2 mg (single oral dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methysergide (dosage not specified)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice daily for 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pizotifen 0.5 mg 3 times daily for 12 days
Number of subjects: 20
Study: 29790790

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28641315

Group type: EXPERIMENTAL
Intervention: Sequential regimen: 4 cycles of epirubicin 90 mg/m² followed by 4 cycles of docetaxel 75 mg/m²
Number of subjects: 658

Group type: COMPARATOR
Intervention: Concurrent regimen: 6 cycles of epirubicin 75 mg/m² plus docetaxel 75 mg/m²
Number of subjects: 658
Study: 25740027

Group type: EXPERIMENTAL
Intervention: Single-cut method (cast bivalve and Ace wrap)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Double-cut method (cast bivalve, spread, and Ace wrap)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Triple-cut method (cast bivalve, spread, Webril cut, and Ace wrap)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ace wrap after cast cutting
Number of subjects: 45
Study: 24617000

Group type: EXPERIMENTAL
Intervention: SIT (standardized allergen vaccine)
Number of subjects: 136
Study: 21411156

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study: 19146133

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with Clearfil New Bond
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with Xeno III
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with AdheSE
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hyposen with Clearfil New Bond
Number of subjects: 90
Study: 16565866

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (n = 18)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo-CPAP (<1 cm H2O) (n = 10)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Supplemental nocturnal oxygen (3 l/min) (n = 16)
Number of subjects: 44
Study: 14601199

Group type: EXPERIMENTAL
Intervention: 2.5 ml 0.75% ropivacaine (18.75 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3 ml 0.75% ropivacaine (22.5 mg)
Number of subjects: 40